Clinical Significance of the Radiological Relationship between the Tumor and the main blood vessels in Enneking IIB Osteosarcoma of the extremities

Qinglin Jin1,2*, Xianbiao Xie1,2*, Hao Yao1,2*, Lili Wen3, Hongbo Li1,2, Dongming Lv1,2, Ziliang Zeng1,2, Yongqian Wang1,2, Changye Zou1,2, Junqiang Yin1,2, Gang Huang1,2, Bo Wang1,2,2, Jingnan Shen1,2

1. Department of Musculoskeletal Oncology Center, The First Affiliated Hospital of Sun Yat-sen University, 58 Zhongshan 2nd Rd, Guangzhou 510080, China.
2. Guangdong Provincial Key Laboratory of Orthopedics and Traumatology, Guangzhou 510080, China.
3. Department of Anesthesiology, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, 651 Dongfengdong Rd, Guangzhou 510060, China.

* These authors have contributed equally to this work.

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/).

Abstract

Aim: Osteosarcoma is one of the most prevalent primary bone malignancies in children and adolescents. Magnetic resonance imaging (MRI) has been considered a very critical tool to provide anatomical information of tumor and surrounding main blood vessels. To evaluate the prognostic significance of the radiological vascular involvement according to the pre-treatment MRI in patients with Enneking IIB osteosarcoma.

Methods: In this retrospective study, we included 482 patients younger than 50 years old with Enneking IIB primary osteosarcoma of the extremities with complete clinical records from 2005 to 2015. Univariate and multivariable analyses were conducted to identify the risk factors for OS (Overall survival) and EFS (Event-free survival). The correlations between the risk factors was performed using Spearman analysis. The Kaplan-Meier method was used to calculate survival curves. Based on the radiological relationship between the tumor lesion and the surrounding reactive area with the main blood vessels as shown on pretreatment MRI findings.

Results: Radiological vascular involvement assessed via pretreatment MRI is an important risk factor for Enneking IIB primary patients with osteosarcoma (HROS=2.32/HRREFS=1.81 P<0.01) according to the univariate and multivariable analyses. Enneking IIB patients with osteosarcoma were assigned to three subtypes based on the radiological relationship between the main blood vessels and the lesion or reactive area. The 5-year cumulative OS of patients classified by the three types were 81.6% (type I), 67.1% (type II) and 44.8% (type III) (P<0.01). The 5-year cumulative EFS of the three types were 60.2% (type I), 46.7% (type II) and 30.2% (type III) (P<0.05). The total 5-year cumulative OS and EFS for all patients were 68.3% and 48.3%, respectively.

Conclusion: Vascular involvement according to radiological findings from pretreatment MRI is an independent risk factor for cumulative OS and EFS in patients with Enneking IIB primary osteosarcoma of the extremities. The new subtyping based on the relationship between the tumors and surrounding reactive area with the main blood vessels based on pretreatment MRI can predict the prognosis of patients with osteosarcoma and provide certain directive information for selecting the appropriate surgical procedure for individual patients.

Key words: Osteosarcoma, Enneking IIB, Reactive Area, Risk Factor, Radiological Vascular Involvement

Introduction

Osteosarcoma is one of the most prevalent primary bone malignancies in children and adolescents [3]. Collectively, osteosarcoma usually originates from the metaphysis of long bones, and the distal femur and proximal tibia are the most common sites of osteosarcoma of the extremities, which comprises over 60% of the reported osteosarcoma diagnoses. With the help of long-standing neoadjuvant and adjuvant chemotherapy, the 5-year

http://www.jcancer.org
cumulative survival rate of osteosarcoma has been elevated to more than 60% since the 1970s [22,24,26].

Enneking et al proposed a classical staging system for malignant bone tumors. This staging system has been widely used by musculoskeletal oncologists to assess the prognosis of patients with osteosarcoma, which also has surgical implications [9]. The vast majority of patients with osteosarcoma are assigned to Enneking stage IIB. However, the prognosis of patients in this group is not uniform. It is not enough to evaluate the prognosis of patients with osteosarcoma or make surgical decisions using the Enneking staging system alone in this group of patients. Increasing evidence indicates that numerous risk factors have been associated with the prognosis of Enneking IIB osteosarcoma. [1-2,4,16-17,19,21]. These risk factors have been individually used in or combined into models to predict the prognosis of Enneking IIB patients with osteosarcoma [14,18,28,30,32]. However, most of those prediction models are utilized after the surgical procedure. The optimal pretreatment prediction model still challenges musculoskeletal oncologists.

Magnetic resonance imaging (MRI) has been considered a very critical imaging tool to provide anatomical information on patients with osteosarcoma upon initial diagnosis. MRI can depict the relationship between the tumor and adjacent neurovascular bundles and the surrounding reactive area [10,34]. Radiological vascular involvement detected by MRI is a risk factor for the prognosis of soft tissue sarcoma [25]. Pretreatment assessments based on MRI data are useful for surgical decisions in soft tissue sarcoma (STS) [5,12,27].

In this study, we first investigated whether radiological involvement of the main blood vessels assessed by MRI is an important prognostic risk factor of patients with Enneking IIB osteosarcoma. Then, we proposed subtyping of Enneking IIB osteosarcoma of extremities based on the relationship between the tumor lesion and surrounding reactive area with the main blood vessels in the pre-treatment MRI, assess its prognostic significance in osteosarcoma patients and potential guidance in selecting surgical procedure individually.

Methods

Study population

In this retrospective study, records of 786 patients who were younger than 50 years old at the time of diagnosis and who were newly diagnosed with osteosarcoma and received standard treatment according to National Comprehensive Cancer Network (NCCN) guidelines from January 2005 to December 2015 at our institution are reviewed.

The inclusion criteria were as follows: (1) patients with histologically confirmed (by needle biopsy) primary high-grade osteosarcoma; (2) patients with tumors located in the extremities; (3) patients who did not receive any antitumor therapy before admission to our center; (4) patients with complete clinical, imaging, pathological and follow-up data; (5) patients who received standard treatment [9].

The exclusion criteria were as follows: (1) patients with evidence of underlying diseases such as hypertension, diabetes, cardiac or pulmonary diseases; (2) patients suffering from another type of tumor or secondary osteosarcoma; (3) patients who received specific treatment in other case-control studies; (4) patients with Enneking stage IIA or III at the time of diagnosis; (5) patients with a Karnofsky performance score<70; (6) patients’ age above 50 years old [20].

After applying the inclusion and exclusion criteria, we finally enrolled 314 (65.1%) patients with distal femoral osteosarcoma, 117 (24.3%) patients with proximal tibial osteosarcoma, 28 (5.8%) patients with proximal humeral osteosarcoma and 23 (4.8%) patients with osteosarcoma at other sites (Table 1).

Diagnoses of osteosarcoma and pulmonary metastasis are based on multidisciplinary factors. X-ray imaging and MRI were performed for local lesions to evaluate tumor size and aggressiveness. A pretreatment needle biopsy of the primary lesion was performed for each patient to confirm the pathological stage of osteosarcoma. Computed tomography (CT) scan of the lung and/or a Positron Emission Tomography-Computed Tomography (PET-CT) scan were also performed to evaluate pulmonary or distant metastasis for osteosarcoma to confirm the Enneking stage. Standard treatment of osteosarcoma involved neoadjuvant chemotherapy, surgery and adjuvant chemotherapy. Four commonly used drugs for neoadjuvant and adjuvant chemotherapy include high-dose methotrexate, cisplatin, doxorubicin, and ifosfamide, which were administered at the interval presented in Figure 1 [33].

Follow-up

Patients were followed up every 3 months for the first and second years, every 4 months for the third year, every 6 months for years 4 and 5, and yearly thereafter. For every follow-up, patient history was taken, and physical examination, X-ray imaging of the lesion site and CT scan of the lungs were performed; PET-CT was performed if potential metastasis or recurrence was noticed.
MR imaging

All patients underwent pretreatment MRI on a 3.0-T MRI system (MR scanners: (1) Siemens Magnetom Trio, Erlangen, Germany; (2) Siemens Magnetom Verio, Erlangen, Germany) with a dedicated eight-channel surface coil or a body coil, depending on the anatomic disease site. MRI acquisition in all cases included sagittal, coronal and transverse T1-weighted (TR 540-750 ms/TE 11-18 ms) and fast spin echo T2-weighted (TR 3500-6460 ms/TE 81-100 ms, echo train length [ETL] 8) with fat suppressed images.

Methods of evaluation

Blood samples were obtained just prior to the initial neoadjuvant chemotherapeutic treatment to measure the alkaline phosphatase (ALP) and lactic dehydrogenase (LDH) levels. Patients were categorized into two distinct age groups (0-14 years; >14 years) [2]. According to the American Joint Committee on Cancer (AJCC), we categorized the maximum tumor diameter into two distinct groups (0-80 mm; >80 mm) [17].

Distinguishing tumor from the peritumoral reactive area was determined according to Lawrence M’s criteria [31]. The maximum diameter of the tumor was defined as the longest diameter of the largest cross-sectional area. The main blood vessels included the main branches of the axillary, brachial, radial, ulnar, femoral, popliteal and posterior tibial artery and vein.

Here, we defined radiological vascular involvement as that when MRI does not show a rim of normal tissue in the tumor/reactive area-to-vessel interface, even if any part of the main blood vessels pass through the tumor lesion or reactive area on the MRI findings [27]. The distance between the tumor lesion, reactive area and main blood vessels on the pretreatment MRI were measured as previously described [33]. We defined NBR: the shortest distance from the center of the main blood vessels to the margin of the reactive area; NBT: the shortest distance from the center of main blood vessels to the margin of tumor lesion (Figure 2). NBR or NBT was noted as 0.00 cm when the main blood vessels were radiologically involved by reactive area or tumor lesion, respectively. The measurement and further subtyping of the radiological relationship between the main blood vessels and tumor lesions or reactive areas was performed independently by two medical imaging specialists, and discussions were carried out when disagreements occurred until achieving a consensus.

Primary outcomes

Overall survival (OS) is defined as the time from diagnosis until death from various causes or until the last follow-up visit.

Event-free survival (EFS) is defined as the time from diagnosis until any event related to the tumor, such as local recurrence, distant metastasis, second primary malignancy, death, etc.

Statistical analysis

SPSS (IBM corp. 22, New York, USA) statistical software was used for statistical analysis. Categorical variables are expressed as numbers and percentages, and the χ2 test was used to compare differences between groups. Continuous variables are presented as the mean (range), and means were compared via ANOVA (Analysis of variance). The correlations between the risk factors were performed using Spearman analysis. Univariate and multivariable analyses were performed to identify the probable
prognostic factors. Variables that were found to be significant in the univariate analysis were included in the multivariable analysis with the Cox proportional hazard model. The Kaplan-Meier method was used to calculate survival curves to estimate OS and EFS; differences between the curves were evaluated with the log-rank test. A P-value<0.05 was considered statistically significant. Intra-observer and inter-observer agreement were assessed by using the Cohen’s kappa statistics. The strength of the kappa agreement was defined as follows: 0.00-0.20 indicated sight agreement; 0.21-0.40 fair agreement; 0.41-0.60, moderate agreement; 0.61-0.80, substantial agreement; and 0.81-1.00, almost perfect agreement.

Results

Patients' characteristics

A total of 482 patients were finally included in our study. The mean age at the time of diagnosis was 19 (range: 7-47) years old, among whom 298 were males (61.8%), and the median follow-up time was 60.0 (range: 28-161) months. Primary site of lesion included distal femur (n = 314 [65.1%]), proximal tibia (n = 117 [24.3%]) and proximal humerus (n = 28 [5.8%]). The mean maximum lesion diameter was 78.3 (range: 38-105) mm. The mean ALP and LDH levels were 234 (range: 49-1546) U/L and 256 (range: 77-1122) U/L, respectively. Furthermore, radiological vascular involvement (RVI) by tumor lesion was detected in 32 (6.6%) patients, while the main blood vessels of 450 (93.4%) patients were free from tumor lesions. Eighty-eight (19.5%) patients underwent amputation, and 394 (81.7%) patients in this study received limb-salvaging surgery (Table 1).

| Characteristics                  |   |
|----------------------------------|---|
| Mean age (Years, Range)          | 19 (7-47) |
| Gender (N, %)                    |   |
| Male                             | 298 (61.8) |
| Female                           | 184 (38.2) |
| Site of tumor (N, %)             |   |
| Distal Femur                     | 314 (65.1) |
| Proximal Tibia                   | 117 (24.3) |
| Proximal Humerus                 | 28 (5.8) |
| Others                           | 23 (4.8) |
| Maximum diameter of tumor (mm, Range) | 78.3 (38-105) |
| Mean ALP (U/L, Range)            | 234 (49-1546) |
| Mean LDH (U/L, Range)            | 256 (77-1122) |
| RVI by tumor lesion (N, %)       |   |
| Involvement                      | 32 (6.6) |
| Uninvolvement                    | 450 (93.4) |
| Histological type (N, %)         |   |
| Osteoblastic                     | 351 (72.8) |
| Chondroblastic                   | 45 (9.3) |
| Fibroblastic                     | 21 (4.4) |
| Other & non-classified           | 65 (13.5) |
| Type of operation (N, %)         |   |
| Limb-salvaging surgery           | 388 (80.5) |
| Amputation                       | 94 (19.5) |

ALP: Alkaline Phosphatase; LDH: Lactic Dehydrogenase; RVI: radiological vascular involvement.

Radiological vascular involvement is an independent risk factor for prognosis in Enneking IIB patients with osteosarcoma

The results of the univariate analysis of the patients are listed in Table 2. According to the univariate analysis, several potential risk factors are closely related to the 5-year cumulative OS and EFS such as the maximum diameter of the tumor lesion, pretreatment ALP levels and radiological vascular involvement (P<0.05) (Table 2). Then, we further
analyzed those independent risk factors via multivariable analysis using a Cox proportional hazard model. As Table 3 shows, interestingly, the maximum diameter of the tumor lesion is most strongly related to the 5-year cumulative OS (Hazard ratio (HR)=2.32, \( P<0.01 \)), while radiological vascular involvement is the strongest independent risk factor for the 5-year cumulative EFS (HR=1.81, \( P<0.01 \)). Figure 3 shows the Kaplan-Meier curve indicating that radiological vascular involvement by tumor lesions is highly related to 5-year cumulative OS and EFS (HR=2.32, \( P<0.01 \)). The 5-year OS and EFS of the group without radiological vascular involvement (the uninvolved group) were 71.7% and 50.9%, respectively, which were significantly higher than those of the group with radiological vascular involvement (the involved group) (44.8% and 30.2%, respectively).

**Subtyping of Enneking IIB osteosarcoma based on the radiological relationship between the tumor and peritumoral reactive area with the main blood vessel**

Vascular involvement is a strong independent risk factor for both 5-year cumulative OS and EFS. Furthermore, we subdivided patients with Enneking IIB osteosarcoma into three different subtypes with the help of MRI data: type I, all main blood vessels are free from the reactive area (NBR=0.00 cm, NBT>0.00 cm); type II, at least one main blood vessel is radiologically involved with the reactive area, while none of main blood vessels are radiologically involved with the tumor lesion (NBR=0.00 cm, NBT>0.00 cm); type III, at least one main blood vessel is radiologically involved with the tumor lesion partly or wholly (NBR=0.00 cm, NBT=0.00 cm). Figure 4 shows the different subtypes of Enneking IIB osteosarcoma with a schematic diagram. Obviously, the green and yellow arrows in the MR image indicate tumor lesions and peritumoral reactive areas, respectively. In the schematic diagram, the green area indicates the tumor lesion, and the yellow area indicates the peritumoral reactive area, which corresponds with the MR image.

Most patients were diagnosed with type II (404, 83.9%), followed by type I (46, 9.5%) and type III (32, 6.6%) (Table 4). The mean ages at the time of diagnosis of the three subtypes were 23 (range: 11-47), 19 (range: 7-47) and 16 (range: 8-29) years old, respectively (\( P<0.05 \)). Most patients had tumors located in the distal femur in type I (65.2%) and type II (68.1%), while most type III (37.5%) patients with osteosarcoma had tumors localized to other sites. The mean maximum diameters of the lesions were 63.2 (range: 39-104) mm, 79.1 (range: 38-105) mm and 84.0 (range: 44-97) mm, respectively (\( P<0.05 \)). The mean NBR were 0.38 (0.31-0.58) cm (type I), 0.00 cm (type II) and 0.00 cm (type III) while the mean NBT were 1.07 (0.69-1.46) cm (type I), 0.35 (0.28-0.44) cm (type II) and 0.00 cm (type III), respectively (\( P<0.05 \)). The mean ALP and LDH levels were also significantly different in the three types of patients. The mean ALP and LDH levels were 179 (range: 52-397) U/L and 225 (range: 86-681) U/L in type I, respectively, which are the lowest among the three subgroups. Furthermore, most patients with type III underwent amputation (\( n = 28, [87.5\%] \)), while only 2 patients of type I underwent amputation surgery (4.3%).

### Table 2. Univariate analysis of probable risk factors for 5-years OS and EFS

| Variable          | Patient (N) | 5-year OS (%) | P-value | Std. (survival) | Patient (N) | 5-year EFS (%) | P-value | Std. (survival) |
|-------------------|-------------|---------------|---------|----------------|-------------|----------------|---------|----------------|
| **Gender**        |             |               |         |                |             |                |         |                |
| Male              | 298         | 66.2          | 0.383   | 5.68           | 298         | 48.1           | 0.598   | 5.78           |
| Female            | 184         | 71.7          |         | 7.06           | 184         | 50.6           | 7.77    |                |
| **Age (years)**   |             |               |         |                |             |                |         |                |
| ≤14               | 160         | 61.2          | 0.094   | 4.54           | 160         | 44.4           | 0.288   | 8.32           |
| >14               | 322         | 71.8          |         | 8.11           | 322         | 50.2           | 4.90    |                |
| **Maximum diameter of tumor (mm)** |           |               |         |                |             |                |         |                |
| ≤80               | 278         | 79.9          | <0.01   | 5.34           | 278         | 54.1           | <0.01   | 6.19           |
| >80               | 204         | 52.8          |         | 6.94           | 204         | 40.1           |         | 6.68           |
| **ALP level**     |             |               |         |                |             |                |         |                |
| Normal            | 186         | 76.3          | 0.040   | 6.51           | 186         | 56.6           | 0.042   | 6.46           |
| Elevated          | 296         | 63.3          |         | 5.95           | 296         | 43.3           |         | 6.02           |
| **LDH level**     |             |               |         |                |             |                |         |                |
| Normal            | 310         | 72.9          | 0.060   | 5.50           | 310         | 50.7           | 0.146   | 5.98           |
| Elevated          | 172         | 60.1          |         | 7.80           | 172         | 43.8           |         | 7.90           |
| **Surgery**       |             |               |         |                |             |                |         |                |
| Amputation        | 94          | 56.5          | 0.112   | 10.29          | 94          | 37.5           | 0.052   | 10.05          |
| Limb-salvage      | 388         | 71.0          |         | 5.00           | 388         | 50.7           |         | 5.30           |
| **RVI by tumor lesion** |       |               |         |                |             |                |         |                |
| Yes               | 32          | 44.8          | <0.01   | 12.26          | 32          | 30.2           | <0.01   | 11.85          |
| No                | 450         | 71.7          |         | 4.77           | 450         | 50.9           |         | 5.13           |

ALP: Alkaline Phosphatase; LDH: Lactic Dehydrogenase; RVI: radiological vascular; OS: Overall survival; EFS: Event-free survival; Std.: standard deviation.

http://www.jcancer.org
Figure 3. 5-year OS (A) and EFS (B) of vascular involvement of Enneking IIB osteosarcoma of extremities. Blue line indicates uninvolved, green line indicates involved. Involved means MR imaging does not show a rim of normal tissue in the tumor-to-vessel interface (P<0.01).

Table 3. Multivariate analysis of clinical factors for 5-year OS and EFS

| Variable                        | Patient (N) | 5-year OS | 5-year EFS |
|---------------------------------|-------------|-----------|------------|
|                                 |             | β-value   | HR         | CI         |
|                                 |             | β-value   | HR         | CI         |
| ALP level                       |             |           |            |            |
| Normal                          | 186         | 0.452     | 1.57       | 0.96-2.56  |
| Elevated                        | 296         | 0.374     | 1.45       | 1.00-2.11  |
| Maximum diameter of tumor       |             |           |            |            |
| ≤80                             | 278         | 1.037     | 2.82       | 1.79-4.44  |
| >80                             | 204         | 0.594     | 1.81       | 1.16-2.83  |
| RVI by tumor lesion             |             |           |            |            |
| Yes                             | 32          | 0.842     | 2.32       | 1.39-3.87  |
| No                              | 450         |           |            |            |

ALP: Alkaline Phosphatase; RVI: radiological vascular; OS: Overall survival; EFS: Event-free survival.

Table 4. Baseline demographic characteristics in three radiological types

| Characteristics                   | Type I (N, %) | Type II (N, %) | Type III (N, %) | P-value |
|-----------------------------------|---------------|---------------|-----------------|---------|
| Mean age (Years, Range)           | 23 (11-47)    | 19 (7-47)     | 16 (8-29)       | <0.05   |
| Gender (N, %)                     |               |               |                 |         |
| Male                              | 32 (69.6)     | 246 (60.9)    | 20 (62.5)       | 0.721   |
| Female                            | 14 (30.4)     | 158 (39.1)    | 12 (37.5)       |         |
| Site of tumor (N, %)              |               |               |                 |         |
| Distal Femur                      | 30 (65.2)     | 275 (68.1)    | 9 (28.1)        | <0.05   |
| Proximal Tibia                    | 8 (17.4)      | 103 (25.5)    | 6 (18.8)        |         |
| Proximal Humerus                  | 2 (4.3)       | 21 (5.2)      | 5 (15.6)        |         |
| Others                            | 6 (13.1)      | 5 (1.2)       | 12 (37.5)       |         |
| Mean ALP (U/L, Range)             | 179 (52-397)  | 222 (49-1546) | 373 (77-1011)   | <0.05   |
| Mean LDH (U/L, Range)             | 225 (86-681)  | 245 (77-1122) | 336 (83-996)    | <0.05   |
| Histological type (N, %)          |               |               |                 |         |
| Osteoblastic                      | 33 (71.1)     | 279 (69.1)    | 23 (71.8)       | 0.398   |
| Chondroblastic                    | 4 (9.5)       | 35 (8.7)      | 3 (9.4)         |         |
| Fibroblastic                      | 2 (4.4)       | 18 (4.5)      | 2 (6.3)         |         |
| Other & non-classified            | 7 (15.2)      | 72 (17.7)     | 4 (12.5)        |         |
| Mean maximum diameter of tumor (mm, Range) | 63.2 (39-104) | 79.1 (38-105) | 84.0 (44-97)   | <0.05   |
| Mean NBR (cm, Range)              | 0.38 (0.31-0.58) | 0.00 | 0.00 | <0.05 |
| Mean NBT (cm, Range)              | 1.07 (0.69-1.46) | 0.35 (0.28-0.44) | 0.00 | <0.05 |
| Type of operation (N, %)          |               |               |                 |         |
| Limb-salvaging surgery            | 44 (95.7)     | 340 (84.2)    | 4 (12.5)        | <0.05   |
| Amputation                        | 2 (4.3)       | 64 (15.8)     | 28 (87.5)       |         |

ALP: Alkaline Phosphatase; LDH: Lactic Dehydrogenase; NBR: Nearest of blood vessels to reactive zone; NBT: Nearest of blood vessels to the tumor.
Clinical significance of pretreatment MRI-based radiological subtyping in Enneking IIB patients with osteosarcoma

To study whether the subtypes of Enneking IIB osteosarcoma defined by the radiological relationship between blood vessels and the lesion or reactive area shown on MRI have differences in survival, we analyzed the 5-year cumulative OS of the three subtypes: 81.6% (type I), 67.1% (type II), and 44.8% (type III), while the total 5-year cumulative OS of Enneking IIB osteosarcoma was 68.3% (P<0.01). Additionally, we analyzed the 5-year cumulative EFS of the three subtypes: 60.2% (type I), 46.7% (type II), and 30.2% (type III). The total EFS of Enneking IIB osteosarcoma was 48.3% in this study (P <0.01) (Figure 5).

In this study, the overall amputation rate was 19.5% (Table 1). The rates of amputation in the subtypes were 4.3% (type I), 15.8% (type II), and 87.5% (type III) (P < 0.01) (Figure 6). One of the type I patients received amputation surgery due to his poor economic condition in which he could not afford high-priced endoprostheses. For the other young type I patient who decided to receive amputation, the patient and family urged amputation because they were worried about the recurrence of the tumor after limb-salvaging surgery. Most type II patients underwent amputation because there was not enough soft tissue to reconstruct after tumor resection. For four type III patients who received limb-salvaging surgery, they all strongly required salvaging the limb. Therefore, we tried to resect the tumor completely.
and separate the partly adhered main blood vessel while excising the vascular sheath in two patients. For the other two whose main blood vessels were completely encompassed by the tumor lesion, we resected the tumor and the involved main blood vessel and utilized a vascular graft to repair the limbs.

**Table 5. Intraobserver and interobserver agreement of radiological classification**

| Type     | Radiologist 1 | Radiologist 2 | Kappa     |
|----------|---------------|---------------|-----------|
|          | First assessment |               |           |
| Type I   | 50            | 41            | 0.603     |
| Type II  | 400           | 406           |           |
| Type III | 32            | 35            |           |
|          | Second assessment |             |           |
| Type I   | 57            | 39            | 0.586     |
| Type II  | 390           | 400           |           |
| Type III | 35            | 43            |           |
| Kappa    | 0.683         | 0.692         |           |

**Intraobserver and interobserver agreement**

With regard to the intraobserver agreement, substantial agreements were observed for subdivision of radiological types (radiologist 1: kappa=0.683, 95% CI: 0.462-0.904; radiologist 2: kappa=0.692, 95% CI: 0.673-0.901). For interobserver agreement between the two radiologists, almost perfect agreement was observed (kappa = 0.595, 95% CI: 0.521-0.668) (Table 5).

**Discussion**

In this study, we investigated the relationships between different types of radiological vascular involvement and survival outcomes for Enneking IIB osteosarcoma of the extremities. To date, the Enneking staging system has been widely accepted and applied by musculoskeletal oncologists throughout the world as a standard classification. However, the majority of patients diagnosed with Enneking IIB osteosarcoma have variable prognoses. Bacci, G et al [1] demonstrated that pretreatment LDH levels should be considered when deciding on a risk-adapted treatment for OS patients. In addition, Bacci,G et al [2] emphasized that age younger than 14 years, high levels of serum ALP, and inadequate surgical margins should be considered when deciding risk-adapted treatment options for patients with osteosarcoma. Kim, M.S.et al [17] suggested that an 80 mm maximal cutoff is strongly useful for subdividing patients with osteosarcoma. According to the Birmingham classification of osteosarcoma [14], a
radiological vascular involvement is an independent risk factor of prognosis in Enneking IIB patients with osteosarcoma.

Tumor cells or satellite lesions may exist within the reactive area detected by MRI, which might involve the main blood vessels and worsen the prognosis of patients with malignancies [7]. As reported by He, F., et al [12], the tumor and peritumoral reactive area measured by MRI are independent risk factors for predicting the prognosis of Enneking IIB patients with osteosarcoma who receive limb-salvaging surgery. White et al reported that a single or cluster of tumor cells were found over 25% of specimens taken in reactive zone [31]. Moreover, Cheon, H, et al [6] demonstrated that peritumoral edema detected by MRI was found in a significantly higher proportion of breast cancer patients with tumor recurrence (50%, P=0.022). In this study, we further subdivided patients into the uninolved group, according to the relationship between the main blood vessel and peritumoral reactive area, and found that the prognosis of patients with main vessels passing through the reactive area was worse than that of patients without. Finally, patients in our study were assigned to three subtypes, and the 5-year cumulative OS rates of the three subtypes were 81.6% (type I), 67.1% (type II), and 44.8% (type III). The EFS rates of the three subtypes were 60.2% (type I), 46.7% (type II), and 30.2% (type III).

According to the pretreatment MRI-based radiological relationship between the main blood vessels and the lesion or reactive area, we classified Enneking IIB osteosarcoma into three subtypes: type I, all main blood vessels are free from the reactive area; type II, at least one main blood vessel is radiologically involved with the reactive area, while none of the main blood vessels are radiologically involved with the lesion; type III, at least one main blood vessel has already been radiologically involved with the lesion partly or wholly. The prognosis of type I patients is the best, while that of type III patients is the worst. This radiological classification procedure via MRI data before treatment is a simple, rapid and noninvasive examination. In addition, surgeons can investigate the initial relationship between the tumor (or reactive area) and the main blood vessels before any changes in involvement are implemented by treatment or examination. Naturally, this new classification can probably provide some initial clues for making surgical decisions. There are several limitations in this study. First, all the patients included were from a single center, which means the findings still need to be validated prior to the application of this classification in other centers.
Second, it’s a retrospective study. Third, we did not evaluate functional assessment in this study.

Conclusion

In conclusion, our study results suggest that the presence of radiological vascular involvement of main blood vessels identified by preoperative MRI is an independent factor associated with the prognosis of Enneking IIB patients with osteosarcoma. The assessment of radiological classification before treatment can provide prognostication for patients with Enneking IIB osteosarcoma, as well as a helpful classification for making surgical decisions for Enneking IIB patients with osteosarcoma.

Abbreviations

CT: Computed tomography; PET-CT: Positron Emission Tomography-Computed Tomography; MRI: Magnetic resonance imaging; OS: Overall survival; EFS: Event-free survival; HR: Hazard ratio; ALP: Alkaline phosphatase; LDH: Lactic dehydrogenase; ANOVA: Analysis of variance; NCCN: National Comprehensive Cancer Network; AJCC: According to the American Joint Committee on Cancer; RVI: Radiological vascular involvement; NBR: Nearest of blood vessels to reactive zone; NBT: Nearest of blood vessels to the tumor.

Acknowledgements

We thank Dr. Zhaohui Zhang and Dr. Lei Ding for assist in design of the study and observing MRI.

Author Contributions

Qinglin Jin, Xianbiao Xie and Hao Yao participated in the design of the study and drafting the article. Lili Wen, Hongbo Li, Dongming Lv and Ziliang Zeng participated in the statistical analysis. Yongqian Wang, Changye Zou, Junqiang Yin and Gang Huang participated in drafting the article. Bo Wang and Jingnan Shen participated in the design of the study and revising the article. All the authors read and approved the final manuscript.

Funding

This work was supported by grants from The National Natural Science Foundation of China (81772861 to Jingnan Shen; 81202118, 81572638, 81972510 and 81772864 to Xianbiao Xie). The funding plays role in study design, collection, analysis, interpretation of data and writing the manuscript.

Ethics approval and consent to participate

The study was granted ethical approval by the Ethical Committee of the First Affiliated Hospital of Sun Yat-sen University, and all the patients provided written informed consent.

Competing Interests

The authors have declared that no competing interest exists.

References

1. Bacci G, Longhi A, Ferrari S, Briccoli A, Donati D, De Paolis M, Versari M. Prognostic significance of serum lactate dehydrogenase in osteosarcoma of the extremity: experience at Rizzoli on 1421 patients treated over the last 30 years. Tumori. 2004; 90(5): 478-484.
2. Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer. 2006; 106(5): 1154-1161.
3. Biermann JS, Chow W, Reed DR, Lucas D, Adkins DR, Agulnik M, Scavone J, L. NCCN Guidelines Insights: Bone Cancer, Version 2.2017. J Natl Compr Canc Netw. 2017; 15(2): 155-167.
4. Bispo JR, Camargo OP. Prognostic factors in the survival of patients diagnosed with primary non-metastatic osteosarcoma with a poor response to neoadjuvant chemotherapy. Clinics (Sao Paulo). 2009; 64(12): 1177-1186.
5. Carneiro A, Bendahla PO, Engellau J, Domanski HA, Fletcher CD, Rispler P, Nilbert M. A prognostic model for soft tissue sarcomas of the extremities and trunk wall based on size, vascular invasion, necrosis, and growth pattern. Cancer. 2011; 117(6): 1279-1289.
6. Chen H, Kim HJ, Kim TH, Ryeom HK, Lee J, Kim GC, Kim WH. Invasive Breast Cancer: Prognostic Value of Peritumoral Edema Identified at Preoperative MR Imaging, Radiology. 2018; 297(1): 68-78.
7. Cohen JF, Hadad H, Schreiber R, Horey G, Katz K, Meller I, Zaizov R. Primary bone tumor resectability: the value of serial MRI studies in the determination of the feasibility, timing, and extent of tumor resection. J Pediatr Orthop. 1994; 14(6): 781-787.
8. Engellau J, Bendahla PO, Penson A, Domanski HA, Akerman M, Gustafson P, Rydholm A. Improved prognostication in soft tissue sarcoma: independent information from vascular invasion, necrosis, growth pattern, and immunostaining using whole-tumor sections and tissue microarrays. Hum Pathol. 2005; 36(9): 994-1002.
9. Enneking WF. A system of staging musculoskeletal neoplasms. Instr Course Lect. 1988; 37: 3-10.
10. Gillespy TR, Manfrini M, Ruggieri P, Spanier SS, Pettersson H, Springfield DS. Staging of intraosseous extent of osteosarcoma: correlation of preoperative CT and MR imaging with pathologic microscides. Radiology. 1988; 167(3): 765-767.
11. Gustafson P, Akerman M, Alvegard TA, Coindre JM, Fletcher CD, Rydholm A, Willen H. Prognostic information in soft tissue sarcoma using tumour size, vascular invasion and microscopic tumour necrosis—the SIN-system. Eur J Cancer. 2003; 39(11): 1568-1576.
12. He F, Qin L, Bao Q, Zang S, He Q, Qiu S, Zhang W. Pre-Operative chemotherapy response assessed by contrast-enhanced MRI can predict the prognosis of Enneking surgical margins in patients with osteosarcoma. J Orthop Res. 2019; 37(1): 258-264.
13. Holzapfel K, Regler J, Baum T, Rechl H, Splecht K, Haller B, Woertler K. Local Staging of Soft-Tissue Sarcoma: Emphasis on Assessment of Neurovascular Encasement-Value of MR Imaging in 174 Confirmed Cases. Radiology. 2015; 275(2): 501-509.
14. Jeys LM, Thorne CJ, Parry M, Gaston CL, Sumathi VP, Grimer JR. A Novel Nomogram to predict the probability of metastasis in Enneking stage IIB extremity osteosarcoma. BMC Cancer. 2011; 11(6): 1279.
15. Kato T, Pezzella F, Steers G, Campo L, Leek RD, Turley H, Fox S. Blood vessel invasion and other variables as predictors of long-term survival in Japanese and British patients with primary invasive breast cancer. Int J Clin Exp Pathol. 2014; 7(11): 7967-7978.
16. Kawaguchi N, Ahmed AR, Matsumoto S, Manabe J, Matsuhashi Y. The concept of curative margin in surgery for bone and soft tissue sarcoma. Clin Orthop Relat Res. 2004; (419): 165-172.
17. Kim MS, Lee SY, Cho WH, Song WS, Koh JS, Lee JA, Jeon DG. An examination of the efficacy of the 8 cm maximal tumor diameter cutoff for the subdivision of AJCC stage II osteosarcoma patients. J Surg Oncol. 2008; 98(6): 427-431.
18. Kim SH, Shin KH, Kim HY, Cho YJ, Noh JK, Suk JS et al. Postoperative nomogram to predict the probability of metastasis in Enneking stage IIB extremity osteosarcoma. BMC Cancer. 2014; 14: 666.
19. Kong CB, Song WS, Cho WH, Oh JM, Jeon DG. Local recurrence has only a small effect on survival in high-risk extremity osteosarcoma. Clin Orthop Relat Res. 2012; 470(5): 1482-1490.
20. Lamsky SB, List MA, Lansky LL, Ritter-Sterr C, Miller DR. The measurement of performance in childhood cancer patients. Cancer. 1987; 60(7): 1651-1656.
21. Marais LC, Bertie J, Rodseth R, Sartorius B, Ferreira N. Pre-treatment serum lactate dehydrogenase and alkaline phosphatase as predictors of metastases in extremity osteosarcoma. J Bone Oncol. 2015;4(3): 80-84.
22. Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 2009; 115(7): 1531-1543.
23. Nagarajan R, Neglia JP, Clohisy DR, Robison LL. Limb salvage and amputation in survivors of pediatric lower-extremity bone tumors: what are the long-term implications? J Clin Oncol. 2002; 20(22): 4493-4501.
24. Ottaviani G, Jaffe N. The epidemiology of osteosarcoma. Cancer Treat Res. 2009; 152: 3-13.
25. Panicek DM, Go SD, Healey JH, Leung DH, Brennan MF, Lewis JJ. Soft-tissue sarcoma involving bone or neurovascular structures: MR imaging prognostic factors. Radiology. 1997; 205(3): 871-875.
26. Schuetze SM. Incremental improvement in osteosarcoma chemotherapy? Ann Oncol. 2017; 28(12): 2911-2913.
27. Schwarzbach MH, Hormann Y, Hinz U, Bernd L, Willeke F, Meckertshheimer G, Allenberg JR. Results of limb-sparing surgery with vascular replacement for soft tissue sarcoma in the lower extremity. J Vasc Surg. 2005; 42(1): 88-97.
28. Tu J, Wen L, Huo Z, Wang B, Wang Y, Liao H et al. Predictive value of dynamic change of haemoglobin levels during therapy on treatment outcomes in patients with Enneking stage IIIB extremity osteosarcoma. BMC Cancer. 2018; 18(1): 428.
29. Veth R, Van HR, Pruszczynski M, Hoogenhout J, Schreuder B, Wobbes T. Limb salvage in musculoskeletal oncology. Lancet Oncol. 2003 4(6): 343-350.
30. Wang S, Zheng S, Hu K, Sun H, Zhang J, Rong G, Gui B. A predictive model to estimate the pretest probability of metastasis in patients with osteosarcoma. Medicine (Baltimore). 2017; 96(5): e5909.
31. White LM, Wunder JS. Histologic assessment of peritumoral edema in soft tissue sarcoma. Int J Radiat Oncol Biol Phys. 2005; 61(5): 1439-45.
32. Wu ZJ, Tan JC, Qin X, Liu B, Yuan ZC. Significance of circulating tumor cells in osteosarcoma patients treated by neoadjuvant chemotherapy and surgery. Cancer Manag Res. 2018; 10: 3333-3339.
33. Yao H, Wang B, Wen L, Jin QL, Li H et al. Comparison of clinical features, management and outcomes of osteosarcoma located in proximal fibula and proximal tibia: a propensity score matching analysis. BMC Cancer. 2018; 18(1): 1195.
34. Zimmer WD, Berquist TH, McLeod RA, Sim FH, Fritchard DJ, Shives TC, May GR. Bone tumors: magnetic resonance imaging versus computed tomography. Radiology. 1985; 155(3): 709-718.